GlycoNex Doses First Patient in Phase I Trial of GNX1021, Advancing Its Glycan-Directed ADC into Clinical Development

Phase 1GNX1021Positive

AI Analysis

Summary

GlycoNex announced the first patient dosing in a Phase I clinical trial of GNX1021, its novel glycan-targeting antibody-drug conjugate, in Japan. This marks the advancement of the company's therapeutic candidate into human clinical development.

Clinical Trial Data

Phase

Phase I

Outcome Details

First patient dosed in Phase I clinical trial

Importance:5/10

Sentiment:

0.60

Phase 1ADCJapanFirst-in-HumanGlycan-targeting

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on August 3, 2026 1:00 AM

Read Original